Lost in transcription: Molecular mechanisms that control HIV latency

Viruses

Volumn 5, Issue 3, 2013, Pages 902-927

  Taube, Ran ^a   Peterlin, Boris Matija ^b,c  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Epigenetic; HIV latency; Positive transcription elongation factor b (P TEFb); Tat; Transcriptional interference

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CTD KINASE; CYCLIN DEPENDENT KINASE; HISTONE DEACETYLASE; PHOSPHOTRANSFERASE; PROTEIN P TEFB; RNA BINDING PROTEIN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ARTICLE; CD4+ T LYMPHOCYTE; CUTANEOUS T CELL LYMPHOMA; DISEASE COURSE; DNA METHYLATION; ENZYME ACTIVITY; ENZYME REGULATION; EPIGENETICS; ERADICATION THERAPY; GENE EXPRESSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MICROBIAL ACTIVITY; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN TARGETING; TRANSCRIPTION ELONGATION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; VIRAL CLEARANCE; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS GENE; VIRUS LATENCY; VIRUS PARTICLE; VIRUS REACTIVATION; VIRUS RESISTANCE; VIRUS TRANSCRIPTION;

ANIMALS; GENE EXPRESSION REGULATION, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTION, GENETIC; VIRUS LATENCY;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84875485322     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v5030902     Document Type: Article

References (189)

1. Lassen, K.; Han, Y.; Zhou, Y.; Siliciano, J.; Siliciano, R.F. The multifactorial nature of HIV-1 latency. Trends Mol. Med. 2004, 10, 525-531.
2. Chun, T.W.; Carruth, L.; Finzi, D.; Shen, X.; DiGiuseppe, J.A.; Taylor, H.; Hermankova, M.; Chadwick, K.; Margolick, J.; Quinn T.C.; et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387, 183-188.
3. Eisele, E.; Siliciano, R.F. Redefining the Viral Reservoirs that Prevent HIV-1 Eradication. Immunity 2012, 37, 377-388.
4. Laughlin, M.A.; Zeichner, S.; Kolson, D.; Alwine, J.C.; Seshamma, T.; Pomerantz, R.J.; Gonzalez-Scarano, F. Sodium butyrate treatment of cells latently infected with HIV-1 results in the expression of unspliced viral RNA. Virology 1993, 196, 496-505.
5. Prins, J.M.; Jurriaans, S.; van Praag, R.M.; Blaak, H.; van Rij, R.; Schellekens, P.T.; ten Berge, I.J.; Yong, S.L.; Fox, C.H.; Roos, M.T.; et al. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 1999, 13, 2405-2410.
6. Popik, W.; Pitha, P.M. Role of tumor necrosis factor alpha in activation and replication of the tat-defective human immunodeficiency virus type 1. J. Virol. 1993, 67, 1094-1099.
7. Folks, T.M.; Justement, J.; Kinter, A.; Dinarello, C.A.; Fauci, A.S. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 1987, 238, 800-802.
8. Poli, G.; Kinter, A.L.; Fauci, A.S. Interleukin 1 induces expression of the human immunodeficiency virus alone and in synergy with interleukin 6 in chronically infected U1 cells: inhibition of inductive effects by the interleukin 1 receptor antagonist. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 108-112.
9. Managlia, E.Z.; Landay, A.; Al-Harthi, L. Interleukin-7 induces HIV replication in primary naive T cells through a nuclear factor of activated T cell (NFAT)-dependent pathway. Virology 2006, 350, 443-452.
10. Chomont, N.; El-Far, M.; Ancuta, P.; Trautmann, L.; Procopio, F.A.; Yassine-Diab, B.; Boucher, G.; Boulasse, M.-R.; Ghatta, G.; Brenchley, J.M.; et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 2009, 15, 893-900.
11. Nabel, G.; Baltimore, D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 1987, 326, 711-713.
12. Zack, J.A.; Arrigo, S.J.; Weitsman, S.R.; Go, A.S.; Haislip, A.; Chen, I.S. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990, 61, 213-222.
13. Stevenson, M.; Stanwick, T.L.; Dempsey, M.P.; Lamonica, C.A. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J. 1990, 9, 1551-1560.
14. Bukrinsky, M.I.; Stanwick, T.L.; Dempsey, M.P.; Stevenson, M. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 1991, 254, 423-427.
15. Luo, Z.; Lin, C.; Shilatifard, A. The super elongation complex (SEC) family in transcriptional control. Nat. Rev. Mol. Cell Biol. 2012, 13, 543-547.
16. Kao, S.Y.; Calman, A.F.; Luciw, P.A.; Peterlin, B.M. Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature 1987, 330, 489-493.
17. Dingwall, C.; Ernberg, I.; Gait, M.J.; Green, S.M.; Heaphy, S.; Karn, J.; Lowe, A.D.; Singh, M.; Skinner, M.A. HIV-1 tat protein stimulates transcription by binding to a U-rich bulge in the stem of the TAR RNA structure. EMBO J. 1990, 9, 4145-4153.
18. Wei, P.; Garber, M.E.; Fang, S.M.; Fischer, W.H.; Jones, K.A. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA Cell 1998, 92, 451-462.
19. Mahmoudi, T.; Parra, M.; Vries, R.G.; Kauder, S.E.; Verrijzer, C.P.; Ott, M.; Verdin, E. The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter. J. Biol. Chem. 2006, 281, 19960-19968.
20. Ott, M.; Dorr, A.; Hetzer-Egger, C.; Kaehlcke, K.; Schnolzer, M.; Henklein, P.; Cole, P.; Zhou, M.M.; Verdin, E. Tat acetylation: a regulatory switch between early and late phases in HIV transcription elongation. Novartis Found. Symp. 2004, 259, 182-193; discussion 193-186, 223-185.
21. Dorr, A.; Kiermer, V.; Pedal, A.; Rackwitz, H.R.; Henklein, P.; Schubert, U.; Zhou, M.M.; Verdin, E.; Ott, M. Transcriptional synergy between Tat and PCAF is dependent on the binding of acetylated Tat to the PCAF bromodomain. EMBO J. 2002, 21, 2715-2723.
22. Kiernan RE, Vanhulle C, Schiltz L, Adam E, Xiao H, Maudoux, F.; Calomme, C.; Burny, A.; Nakatani, Y.; Jeang, K.T.; et al. HIV-1 tat transcriptional activity is regulated by acetylation. EMBO J. 1999, 18, 6106-6118.
23. Boulanger, M.C.; Liang, C.; Russell, R.S.; Lin, R.; Bedford, M.T.; Wainberg, M.A.; Richard, S. Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene expression. J. Virol. 2005, 79, 124-131.
24. Treand, C.; du Chene, I.; Bres, V.; Kiernan, R.; Benarous, R.; Benkirane, M.; Emiliani, S.; et al. Requirement for SWI/SNF chromatin-remodeling complex in Tat-mediated activation of the HIV-1 promoter. EMBO J. 2006, 25, 1690-1699.
25. Yamaguchi, Y.; Takagi, T.; Wada, T.; Yano, K.; Furuya, A.; Sugimoto, S.; Hasegawa, J.; Handa, H. NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation. Cell 1999, 97, 41-51.
26. Yamaguchi, Y.; Wada, T.; Watanabe, D.; Takagi, T.; Hasegawa, J.; Handa, H. Structure and function of the human transcription elongation factor DSIF. J. Biol. Chem. 1999, 274, 8085-8092.
27. Narita, T.; Yamaguchi, Y.; Yano, K.; Sugimoto, S.; Chanarat, S.; Wada, T.; Kim, D.-K.; Hasegawa, J.; Omori, M.; Inukai, N.; et al. Human transcription elongation factor NELF: identification of novel subunits and reconstitution of the functionally active complex. Mol. Cell. Biol. 2003, 23, 1863-1873.
28. Marciniak, R.A.; Calnan, B.J.; Frankel, A.D.; Sharp, P.A. HIV-1 Tat protein trans-activates transcription in vitro. Cell 1990, 63, 791-802.
29. Mancebo, H.S.; Lee, G.; Flygare, J.; Tomassini, J.; Luu, P.; Zhu, Y.; Peng, J.; Blau, C.; Hazuda, D.; Price, D.; et al. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes. Dev. 1997, 11, 2633-2644.
30. Zhu, Y.; Pe'ery, T.; Peng, J.; Ramanathan, Y.; Marshall, N.; Marshall, T.; Amendt, B.; Mathews, M.B.; Price, D.H. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev. 1997, 11, 2622-2632.
31. Kim, H.; Erickson, B.; Luo, W.; Seward, D.; Graber, J.H.; Pollock, D.D.; Megee, P.C.; Bentley, D.L. Gene-specific RNA polymerase II phosphorylation and the CTD code. Nat. Struct. Mol. Biol. 2010, 17, 1279-1286.
32. Lenasi, T.; Peterlin, B.M.; Dovc, P. Distal regulation of alternative splicing by splicing enhancer in equine beta-casein intron 1. RNA, 2006, 12, 498-507.
33. Gu, B.; Eick, D.; Bensaude, O. CTD serine-2 plays a critical role in splicing and termination factor recruitment to RNA polymerase II in vivo. Nucleic. Acids. Res. 2013, 41(3) 1591-1603.
34. Marshall, N.F.; Peng, J.; Xie, Z.; Price, D.H. Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase. J. Biol. Chem. 1996, 271, 27176-27183.
35. Marshall, N.F.; Price, D.H. Purification of P-TEFb, a transcription factor required for the transition into productive elongation. J. Biol. Chem. 1995, 270, 12335-12338.
36. Marciniak, R.A.; Sharp, P.A. HIV-1 Tat protein promotes formation of more-processive elongation complexes. EMBO J. 1991, 10, 4189-4196.
37. Yang, X.; Herrmann, C.H.; Rice, A.P. The human immunodeficiency virus Tat proteins specifically associate with TAK in vivo and require the carboxyl-terminal domain of RNA polymerase II for function. J. Virol. 1996, 70, 4576-4584.
38. Gold, M.O.; Yang, X.; Herrmann, C.H.; Rice, A.P. PITALRE, the catalytic subunit of TAK, is required for human immunodeficiency virus Tat transactivation in vivo. J. Virol. 1998, 72, 4448-4453.
39. Yang, X.; Gold, M.O.; Tang, D.N.; Lewis, D.E.; Aguilar-Cordova, E.; Rice, A.P.; Herrmann, C.H. TAK, an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines. Proc. Natl. Acad. Sci. U S A, 1997 94, 12331-12336.
40. Herrmann, C.H.; Rice, A.P. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor. J. Virol. 1995, 69, 1612-1620.
41. Kephart, D.D.; Marshall N.F.; Price D.H. Stability of Drosophila RNA polymerase II elongation complexes in vitro. Mol. Cell. Biol. 1992, 12, 2067-2077.
42. Alonso A.; Cujec T.P.; Peterlin B.M. Effects of human chromosome 12 on interactions between Tat and TAR of human immunodeficiency virus type 1. J. Virol. 1994, 68, 6505-6513.
43. Alonso A.; Derse D.; Peterlin B.M. Human chromosome 12 is required for optimal interactions between Tat and TAR of human immunodeficiency virus type 1 in rodent cells. J. Virol. 1992, 66, 4617-4621.
44. Garber M.E.; Wei P.; KewalRamani V.N.; Mayall T.P.; Herrmann C.H.; Rice A.P.; Littman D.R.; Jones K.A. The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev. 1998, 12, 3512-3527.
45. De Luca A.; De Falco M.; Baldi A.; Paggi M.G. Cyclin T: three forms for different roles in physiological and pathological functions. J. Cell. Physiol. 2003, 194, 101-107.
46. Sung T.L.; Rice A.P. Effects of prostratin on Cyclin T1/P-TEFb function and the gene expression profile in primary resting CD4+ T cells. Retrovirology, 2006, 3, 66.
47. Ramakrishnan, R.; Yu, W.; Rice, A.P. Limited redundancy in genes regulated by Cyclin T2 and Cyclin T1. BMC Res. Notes, 2011, 4, 260.
48. Kohoutek, J.; Li, Q.; Blazek, D.; Luo, Z.; Jiang, H.; Peterlin, B.M. Cyclin T2 is essential for mouse embryogenesis. Mol. Cell. Biol. 2009, 29, 3280-3285.
49. De Luca, A.; Tosolini, A.; Russo, P.; Severino, A.; Baldi, A.; et al. Cyclin T2a gene maps on human chromosome 2q21. J. Histochem. Cytochem. 2001, 49, 693-698.
50. Blazek, D.; Kohoutek, J.; Bartholomeeusen, K.; Johansen, E.; Hulinkova, P.; Luo, Z.; Cimermancic, P.; Ule J.; Peterlin, B.M. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev. 2011, 25, 2158-2172.
51. Kohoutek, J.; Blazek, D. Cyclin K goes with Cdk12 and Cdk13. Cell Div. 2012, 7, 12.
52. Blazek D. The cyclin K/Cdk12 complex: an emerging new player in the maintenance of genome stability. Cell Cycle, 2012, 11, 1049-1050.
53. Bartkowiak, B.; Liu, P.; Phatnani, H.P.; Fuda, N.J.; Cooper, J.J.; Price, D.H.; Adelman, K.; Lis, J.T.; Greenleaf, A.L. CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1. Genes. Dev. 2010, 24, 2303-2316.
54. Dai, Q.; Lei, T.; Zhao, C.; Zhong, J.; Tang, Y.Z.; Chen, B.; Yang, J.; Li, C.; Wang, S.; Song, X.; Li, L.; Li, Q. Cyclin K-containing kinase complexes maintain self-renewal in murine embryonic stem cells. J. Biol. Chem. 2012, 287, 25344-25352.
55. Peterlin, B.M.; Price, D.H. Controlling the elongation phase of transcription with P-TEFb. Mol. Cell. 2006, 23, 297-305.
56. Adelman, K.; Lis, J.T. Promoter-proximal pausing of RNA polymerase II: emerging roles in metazoans. Nat. Rev. Genet. 2012, 13, 720-731.
57. Core, L.J.; Lis, J.T. Transcription regulation through promoter-proximal pausing of RNA polymerase II. Science, 2008, 319, 1791-1792.
58. Kanazawa, S.; Okamoto, T.; Peterlin, B.M. Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection. Immunity, 2000, 12, 61-70.
59. Kanazawa, S.; Soucek, L.; Evan, G.; Okamoto, T.; Peterlin, B.M. c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis. Oncogene, 2003, 22, 5707-5711.
60. Kornblihtt, A.R.; de la Mata, M.; Fededa, J.P.; Munoz, M.J.; Nogues, G. Multiple links between transcription and splicing. RNA, 2004, 10, 1489-1498.
61. Glover-Cutter, K.; Larochelle, S.; Erickson, B.; Zhang, C.; Shokat, K.; Fisher, R.P.; Bentley, D.L. TFIIH-associated Cdk7 kinase functions in phosphorylation of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by RNA polymerase II. Mol. Cell. Biol. 2009, 29, 5455-5464.
62. Cho, E.J.; Takagi, T.; Moore, C.R.; Buratowski, S. mRNA capping enzyme is recruited to the transcription complex by phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev. 1997, 11, 3319-3326.
63. Wen, Y.; Shatkin, A.J. Transcription elongation factor hSPT5 stimulates mRNA capping. Genes Dev. 1999, 13, 1774-1779.
64. Ahn, S.H.; Kim, M.; Buratowski, S. Phosphorylation of serine 2 within the RNA polymerase II C-terminal domain couples transcription and 3' end processing. Mol. Cell. 2004, 13, 67-76.
65. Barboric, M.; Lenasi, T.; Chen, H.; Johansen, E.B.; Guo, S.; Peterlin, B.M. 7SK snRNP/P-TEFb couples transcription elongation with alternative splicing and is essential for vertebrate development. Proc. Natl. Acad. Sci. U S A, 2009, 106, 7798-7803.
66. Pirngruber, J.; Shchebet, A.; Schreiber, L.; Shema, E.; Minsky, N.; Chapman, R.D.; Eick, D.; Aylon, Y.; Oren, M.; Johnsen, S.A. CDK9 directs H2B monoubiquitination and controls replication-dependent histone mRNA 3'-end processing. EMBO Rep. 2009, 10, 894-900.
67. Lenasi, T.; Peterlin, B.M.; Barboric, M. Cap-binding protein complex links pre-mRNA capping to transcription elongation and alternative splicing through positive transcription elongation factor b (P-TEFb). J. Biol. Chem. 2011, 286, 22758-22768.
68. Bres, V.; Gomes, N.; Pickle, L.; Jones, K.A. A human splicing factor, SKIP, associates with P-TEFb and enhances transcription elongation by HIV-1 Tat. Genes Dev. 2005, 19, 1211-1226.
69. Berro, R.; Kehn, K.; de la Fuente, C.; Wade, J.; Colberg-Poley, A.M.; Berro, R. Acetylated Tat regulates human immunodeficiency virus type 1 splicing through its interaction with the splicing regulator p32. J. Virol. 2006, 80, 3189-3204.
70. Bohne, J.; Krausslich, H.G. Mutation of the major 5' splice site renders a CMV-driven HIV-1 proviral clone Tat-dependent: connections between transcription and splicing. FEBS Lett. 2004, 563, 113-118.
71. Chiu, Y.L.; Coronel, E.; Ho, C.K.; Shuman, S.; Rana, T.M. HIV-1 Tat protein interacts with mammalian capping enzyme and stimulates capping of TAR RNA. J. Biol. Chem. 2001, 276, 12959-12966.
72. Chiu, Y.L.; Ho, C.K.; Saha, N.; Schwer, B.; Shuman, S.; Rana, T.M. Tat stimulates cotranscriptional capping of HIV mRNA. Mol. Cell. 2002, 10, 585-597.
73. Tahirov, T.H.; Babayeva, N.D.; Varzavand, K.; Cooper, J.J.; Sedore, S.C.; Price, D.H. Crystal structure of HIV-1 Tat complexed with human P-TEFb. Nature, 2010, 465, 747-751.
74. Finzi, D.; Hermankova, M.; Pierson, T.; Carruth, L.M.; Buck, C.; et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science, 1997, 278, 1295-1300.
75. Pierson, T.; McArthur, J.; Siliciano, R.F. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu. Rev. Immunol. 2000, 18, 665-708.
76. Bintu, L.; Ishibashi, T.; Dangkulwanich, M.; Wu, Y.Y.; Lubkowska, L.; Kashlev, M.; Bustamante, C. Nucleosomal elements that control the topography of the barrier to transcription. Cell, 2012, 151, 738-749.
77. Van Lint, C.; Emiliani, S.; Ott, M.; Verdin, E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J. 1996, 15, 1112-1120.
78. Mbonye, U.; Karn, J. Control of HIV latency by epigenetic and non-epigenetic mechanisms. Curr. HIV Res. 2011, 9, 554-567.
79. Coiras, M.; Lopez-Huertas, M.R.; Perez-Olmeda, M.; Alcami, J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat. Rev. Microbiol. 2009, 7, 798-812.
80. du Chene, I.; Basyuk, E.; Lin, Y.L.; Triboulet, R.; Knezevich, A.; et al. Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and postintegration latency. EMBO J. 2007, 26, 424-435.
81. Marban, C.; Suzanne, S.; Dequiedt, F.; de Walque, S.; Redel, L.; Van Lint, C.; Aunis, D.; Rohr, O. Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J. 2007, 26, 412-423.
82. Imai, K.; Togami, H.; Okamoto, T. Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. J. Biol. Chem. 2010, 285, 16538-16545.
83. Coull, J.J.; Romerio, F.; Sun, J.M.; Volker, J.L.; Galvin, K.M.; Davie, J.R.; Shi, Y.; Hansen, U.; Margolis, D.M. The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J. Virol. 2000, 74, 6790-6799.
84. Keedy, K.S.; Archin, N.M.; Gates, A.T.; Espeseth, A.; Hazuda, D.J.; Margolis, D.M. A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J. Virol. 2009, 83, 4749-4756.
85. Margolis, D.M.; Somasundaran, M.; Green, M.R. Human transcription factor YY1 represses human immunodeficiency virus type 1 transcription and virion production. J. Virol. 1994, 68, 905-910.
86. Tyagi, M.; Pearson, R.J.; Karn, J. Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J. Virol. 2010, 84, 6425-6437.
87. Tyagi, M.; Karn, J. CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J. 2007, 26, 4985-4995.
88. Kauder, S.E.; Bosque, A.; Lindqvist, A.; Planelles, V.; Verdin, E. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog. 2009, 5, e1000495.
89. Williams, S.A.; Kwon, H.; Chen, L.F.; Greene, W.C. Sustained induction of NF-kappa B is required for efficient expression of latent human immunodeficiency virus type 1. J. Virol. 2007, 81, 6043-6056.
90. Bosque, A.; Planelles, V. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood, 2009, 113, 58-65.
91. Kinoshita, S.; Su, L.; Amano, M.; Timmerman, L.A.; Kaneshima, H.; Nolan, G.P. The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. Immunity, 1997, 6, 235-244.
92. Bednarik, D.P.; Cook, J.A.; Pitha, P.M. Inactivation of the HIV LTR by DNA CpG methylation: evidence for a role in latency. EMBO J. 1990, 9, 1157-1164.
93. Rafati, H.; Parra, M.; Hakre, S.; Moshkin, Y.; Verdin, E.; Mahmoudi, T. Repressive LTR nucleosome positioning by the BAF complex is required for HIV latency. PLoS Biol. 2011, 9, e1001206.
94. Han, Y.; Lassen, K.; Monie, D.; Sedaghat, A.R.; Shimoji, S.; et al. Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J. Virol. 2004, 78, 6122-6133.
95. Shan, L.; Yang, H.C.; Rabi, S.A.; Bravo, H.C.; Shroff, N.S.; Irizarry, R.A.; Zhang, H.; Margolick, J.B.; Siliciano, J.D.; Siliciano, R.F. Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model. J. Virol. 2011, 85, 5384-5393.
96. Michel, F.; Crucifix, C.; Granger, F.; Eiler, S.; Mouscadet, J.F.; et al. Structural basis for HIV-1 DNA integration in the human genome, role of the LEDGF/P75 cofactor. EMBO J. 2009, 28, 980-991.
97. Schroder, A.R.; Shinn, P.; Chen, H.; Berry, C.; Ecker, J.R.; Bushman, F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell, 2002, 110, 521-529.
98. Jordan, A.; Defechereux, P.; Verdin, E. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J. 2001, 20, 1726-1738.
99. Lewinski, M.K.; Bisgrove, D.; Shinn, P.; Chen, H.; Hoffmann, C.; Hannenhalli, S.; Verdin, E.; Berry, C.C.; Ecker, J.R.; Bushman, F.D. Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. J. Virol. 2005, 79, 6610-6619.
100. Bushman, F.; Lewinski, M.; Ciuffi, A.; Barr, S.; Leipzig, J.; Hannenhalli, S.; Hoffmann, C. Genome-wide analysis of retroviral DNA integration. Nat. Rev. Microbiol. 2005, 3, 848-858.
101. Siliciano, R.F.; Greene, W.C. HIV Latency. Cold Spring. Harb. Perspect. Med. 2011, 1, a007096.
102. Chan, J.K.; Greene, W.C. NF-kappaB/Rel: agonist and antagonist roles in HIV-1 latency. Curr. Opin. HIV AIDS, 2011, 6, 12-18.
103. Han, Y.; Lin, Y.B.; An, W.; Xu, J.; Yang, H.C.; O'Connell, K.; Dordai, D.; Boeke, J.D.; Siliciano, J.D.; Siliciano, RF. Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell. Host. Microbe. 2008, 4, 134-146.
104. Nguyen, V.T.; Kiss, T.; Michels, A.A.; Bensaude, O. 7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes. Nature, 2001, 414, 322-325.
105. Peterlin, B.M.; Brogie, J.E.; Price, D.H. 7SK snRNA: a noncoding RNA that plays a major role in regulating eukaryotic transcription. Wiley Interdiscip. Rev. RNA, 2012, 3(1) 92-103.
106. Cho, S.; Schroeder, S.; Kaehlcke, K.; Kwon, H.S.; Pedal, A.; Herker, E.; Schnoelzer, M.; Ott, M. Acetylation of cyclin T1 regulates the equilibrium between active and inactive P-TEFb in cells. EMBO J. 2009, 28, 1407-1417.
107. Zhou, Q.; Li T.; Price, D.H. RNA Polymerase II Elongation Control. Annu. Rev. Biochem. 2012, 81, 119-143.
108. Dey, A.; Chitsaz, F.; Abbasi, A.; Misteli, T.; Ozato, K. The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc. Natl. Acad. Sci. U S A, 2003, 100, 8758-8763.
109. Bisgrove, D.A.; Mahmoudi, T.; Henklein, P.; Verdin, E. Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. Proc. Natl. Acad. Sci. U. S. A., 2007, 104, 13690-13695
110. Chen, R.; Liu, M.; Li, H.; Xue, Y.; Ramey, W.N.; et al. PP2B and PP1alpha cooperatively disrupt 7SK snRNP to release P-TEFb for transcription in response to Ca2+ signaling. Genes Dev. 2008, 22, 1356-1368.
111. Chiang, C.M. Brd4 engagement from chromatin targeting to transcriptional regulation: selective contact with acetylated histone H3 and H4. F1000 Biol. Rep. 2009, 1, 98.
112. Ai, N.; Hu, X.; Ding, F.; Yu, B.; Wang, H. et al. Signal-induced Brd4 release from chromatin is essential for its role transition from chromatin targeting to transcriptional regulation. Nucleic. Acids Res. 2011, 39, 9592-9604.
113. Schroder, S.; Cho, S.; Zeng, L.; Zhang, Q.; Kaehlcke, K.; et al. Two-pronged binding with bromodomain-containing protein 4 liberates positive transcription elongation factor b from inactive ribonucleoprotein complexes. J. Biol. Chem. 2012, 287, 1090-1099.
114. Takahashi, H.; Parmely, T.J.; Sato, S.; Tomomori-Sato, C.; Banks, C.A.; et al. Human mediator subunit MED26 functions as a docking site for transcription elongation factors. Cell, 2011, 146, 92-104.
115. Zhao, R.; Nakamura, T.; Fu, Y.; Lazar, Z.; Spector, D.L. Gene bookmarking accelerates the kinetics of post-mitotic transcriptional re-activation. Nat. Cell. Biol. 2011, 13, 1295-1304.
116. Casse, C.; Giannoni, F.; Nguyen, V.T.; Dubois, M.F.; Bensaude, O. The transcriptional inhibitors, actinomycin D and alpha-amanitin, activate the HIV-1 promoter and favor phosphorylation of the RNA polymerase II C-terminal domain. J. Biol. Chem. 1999, 274, 16097-16106.
117. Michels, A.A.; Fraldi, A.; Li, Q.; Adamson, T.E.; Bonnet, F.; et al. Binding of the 7SK snRNA turns the HEXIM1 protein into a P-TEFb (CDK9/cyclin T) inhibitor. EMBO J. 2004, 23, 2608-2619.
118. Michels, A.A.; Nguyen, V.T.; Fraldi, A.; Labas, V.; Edwards, M.; Bonnet, F.; Lania, L.; Bensaude, O. MAQ1 and 7SK RNA interact with CDK9/cyclin T complexes in a transcription-dependent manner. Mol. Cell. Biol. 2003, 23, 4859-4869.
119. Yik, J.H.; Chen, R.; Pezda, A.C.; Samford, C.S.; Zhou, Q. A human immunodeficiency virus type 1 Tat-like arginine-rich RNA-binding domain is essential for HEXIM1 to inhibit RNA polymerase II transcription through 7SK snRNA-mediated inactivation of P-TEFb. Mol. Cell. Biol. 2004, 24, 5094-5105.
120. Budhiraja, S.; Ramakrishnan, R.; Rice, A.P. (2012) Phosphatase PPM1A negatively regulates P-TEFb function in resting CD4T+ T cells and inhibits HIV-1 gene expression. Retrovirology 9, 52.
121. Chiang, K.; Sung, T.L.; Rice, A.P. Regulation of cyclin T1 and HIV-1 Replication by microRNAs in resting CD4+ T lymphocytes. J. Virol. 2012, 86, 3244-3252.
122. Ramakrishnan, R.; Dow, E.C.; Rice, A.P. Characterization of Cdk9 T-loop phosphorylation in resting and activated CD4(+) T lymphocytes. J. Leukoc. Biol. 2009, 86, 1345-1350.
123. Ramakrishnan, R.; Rice, A.P. Cdk9 T-loop phosphorylation is regulated by the calcium signaling pathway. J. Cell. Physiol. 2012, 227, 609-617.
124. Ghose, R.; Liou, L.Y.; Herrmann, C.H.; Rice, A.P. Induction of TAK (cyclin T1/P-TEFb) in purified resting CD4(+) T lymphocytes by combination of cytokines. J. Virol. 2001, 75, 11336-11343.
125. Liou, L.Y.; Herrmann, C.H.; Rice, A.P. Human immunodeficiency virus type 1 infection induces cyclin T1 expression in macrophages. J. Virol. 2004, 78, 8114-8119.
126. Liou, L.Y.; Herrmann, C.H.; Rice, A.P. HIV-1 infection and regulation of Tat function in macrophages. Int. J. Biochem. Cell. Biol. 2004, 36, 1767-1775.
127. Sung, T.L.; Rice, A.P. miR-198 inhibits HIV-1 gene expression and replication in monocytes and its mechanism of action appears to involve repression of cyclin T1. PLoS Pathog. 2009, 5, e1000263.
128. Yu, W.; Ramakrishnan, R.; Wang, Y.; Chiang, K.; Sung, T.L.; Rice, A.P. Cyclin T1-dependent genes in activated CD4 T and macrophage cell lines appear enriched in HIV-1 co-factors. PLoS One, 2008 3, e3146.
129. Hoque, M.; Shamanna, R.A.; Guan, D.; Pe'ery, T.; Mathews, M.B. HIV-1 replication and latency are regulated by translational control of cyclin T1. J. Mol. Biol. 2011, 410, 917-932.
130. Fong, Y.W.; Zhou, Q. Relief of two built-In autoinhibitory mechanisms in P-TEFb is required for assembly of a multicomponent transcription elongation complex at the human immunodeficiency virus type 1 promoter. Mol. Cell. Biol. 2000, 20, 5897-5907.
131. Garber, M.E.; Mayall, T.P.; Suess, E.M.; Meisenhelder, J.; Thompson, N.E.; Jones, K.A. CDK9 autophosphorylation regulates high-affinity binding of the human immunodeficiency virus type 1 tat-P-TEFb complex to TAR RNA. Mol. Cell. Biol. 2000, 20, 6958-6969.
132. Baumli, S.; Lolli, G.; Lowe, E.D.; Troiani, S.; Rusconi, L.; Bullock, A.N.; Debreczeni, J.E.; Knapp, S.; Johnson, L.N. The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. EMBO J. 2008, 27, 1907-1918
133. Zhou, Q.; Chen, D.; Pierstorff, E.; Luo, K. Transcription elongation factor P-TEFb mediates Tat activation of HIV-1 transcription at multiple stages. EMBO J. 1998, 17, 3681-3691.
134. Vollmuth, F.; Blankenfeldt, W.; Geyer, M. Structures of the dual bromodomains of the P-TEFb-activating protein Brd4 at atomic resolution. J. Biol. Chem. 2009, 284, 36547-36556
135. Liu, H.; Rice, A.P. Genomic organization and characterization of promoter function of the human CDK9 gene. Gene, 2000, 252, 51-59.
136. Bagella, L.; Stiegler, P.; De Luca, A.; Siracusa, L.D.; Giordano, A. Genomic organization, promoter analysis, and chromosomal mapping of the mouse gene encoding Cdk9. J. Cell. Biochem. 2000, 78, 170-178.
137. Herrmann, C.H.; Mancini, M.A. The Cdk9 and cyclin T subunits of TAK/P-TEFb localize to splicing factor-rich nuclear speckle regions. J. Cell. Sci. 2001, 114, 1491-1503
138. Pendergrast, P.S.; Wang, C.; Hernandez, N.; Huang, S. FBI-1 can stimulate HIV-1 Tat activity and is targeted to a novel subnuclear domain that includes the Tat-P-TEFb-containing nuclear speckles. Mol. Biol. Cell. 2002, 13, 915-929.
139. Liu, H.; Herrmann, C.H. Differential localization and expression of the Cdk9 42k and 55k isoforms. J. Cell. Physiol. 2005, 203, 251-260.
140. Chen, R.; Yang, Z.; Zhou, Q. Phosphorylated positive transcription elongation factor b (P-TEFb) is tagged for inhibition through association with 7SK snRNA. J. Biol. Chem. 2004, 279, 4153-4160.
141. Barboric, M.; Zhang, F.; Besenicar, M.; Plemenitas, A.; Peterlin, B.M. Ubiquitylation of Cdk9 by Skp2 facilitates optimal Tat transactivation. J. Virol. 2005, 79, 11135-11141
142. Sabo, A.; Lusic, M.; Cereseto, A.; Giacca, M. Acetylation of conserved lysines in the catalytic core of cyclin-dependent kinase 9 inhibits kinase activity and regulates transcription. Mol. Cell. Biol. 2008, 28, 2201-2212.
143. Yang, Z.; Yik, J.H.; Chen, R.; He, N.; Jang, M.K.; Ozato, K.; Zhou, Q. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol. Cell. 2005, 19, 535-545.
144. Li, Q.; Price, J.P.; Byers, S.A.; Cheng, D.; Peng, J.; Price, D.H. Analysis of the large inactive P-TEFb complex indicates that it contains one 7SK molecule, a dimer of HEXIM1 or HEXIM2, and two P-TEFb molecules containing Cdk9 phosphorylated at threonine 186. J. Biol. Chem. 2005, 280, 28819-28826.
145. Russo, A.A.; Jeffrey, P.D.; Pavletich, N.P. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat. Struct. Biol. 1996, 3, 696-700.
146. Zhou, M.; Nekhai, S.; Bharucha, D.C.; Kumar, A.; Ge, H.; Price, D.H.; Egly, J.M.; Brady, J.N. TFIIH inhibits CDK9 phosphorylation during human immunodeficiency virus type 1 transcription. J. Biol. Chem. 2001, 276, 44633-44640.
147. Breuer, D.; Kotelkin, A.; Ammosova, T.; Kumari, N.; Ivanov, A.; et al. CDK2 regulates HIV-1 transcription by phosphorylation of CDK9 on serine 90. Retrovirology, 2012, 9, 94
148. Larochelle, S.; Amat, R.; Glover-Cutter, K.; Sansó, M.; Zhang, C.; Allen, J.J.; Shokat, K.M.; Bentley, D.L.; Fisher, R.P. Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. Nat. Struct. Mol. Biol. 2012, 19, 1108-1115.
149. Ammosova, T.; Obukhov, Y.; Kotelkin, A.; Breuer, D.; Beullens, M.; Gordeuk, V.R.; Bollen, M. Nekhai, S. Protein phosphatase-1 activates CDK9 by dephosphorylating Ser175. PLoS One, 2011, 6: e18985.
150. Ammosova, T.; Yedavalli, V.R.; Niu, X.; Jerebtsova, M.; Van Eynde, A.; Beullens, M.; Bollen, M.; Jeang, K.T.; Nekhai, S. Expression of a protein phosphatase 1 inhibitor, cdNIPP1, increases CDK9 threonine 186 phosphorylation and inhibits HIV-1 transcription. J. Biol. Chem. 2011, 286, 3798-3804.
151. Wang, Y.; Dow, E.C.; Liang, Y.Y.; Ramakrishnan, R.; Liu, H.; Sung, T.L.; Lin, X.; Rice, A.P. Phosphatase PPM1A regulates phosphorylation of Thr-186 in the Cdk9 T-loop. J. Biol. Chem. 2008, 283, 33578-33584.
152. Kiernan, R.E.; Emiliani, S.; Nakayama, K.; Castro, A.; Labbé, J.C.; Lorca, T.; Nakayama, K K.; Benkirane, M. Interaction between cyclin T1 and SCF(SKP2) targets CDK9 for ubiquitination and degradation by the proteasome. Mol. Cell. Biol. 2001, 21, 7956-7970
153. Fu, J.; Yoon, H.G.; Qin, J.; Wong, J. Regulation of P-TEFb elongation complex activity by CDK9 acetylation. Mol. Cell. Biol. 2007, 27, 4641-4651.
154. Sobhian, B.; Laguette, N.; Yatim, A.; Nakamura, M.; Levy, Y.; Kiernan, R.; Benkirane, M. HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP. Mol. Cell. 2010, 38, 439-451.
155. He, N.; Liu, M.; Hsu, J.; Xue, Y.; Chou, S.; Burlingame, A.; Krogan, N.J.; Alber, T.; Zhou, Q. HIV-1 Tat and host AFF4 recruit two transcription elongation factors into a bifunctional complex for coordinated activation of HIV-1 transcription. Mol. Cell. 2010, 38, 428-438
156. Yokoyama, A.; Lin, M.; Naresh, A.; Kitabayashi, I.; Cleary, M.L. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell, 2010,17, 198-212.
157. Shilatifard, A.; Conaway, R.C.; Conaway, J.W. The RNA polymerase II elongation complex. Annu. Rev. Biochem. 2003, 72, 693-715.
158. Shilatifard, A.; Lane, W.S.; Jackson, K.W.; Conaway, R.C.; Conaway, J.W. An RNA polymerase II elongation factor encoded by the human ELL gene. Science, 1996, 271, 1873-1876.
159. Shilatifard, A.; Duan, D.R.; Haque, D.; Florence, C.; Schubach, W.H.; Conaway, J.W.; Conaway, R.C. ELL2, a new member of an ELL family of RNA polymerase II elongation factors. Proc. Natl. Acad. Sci. U S A, 1997, 94: 3639-3643.
160. He, N.; Chan, C.K.; Sobhian, B.; Chou, S.; Xue, Y.; Liu, M.; Alber, T.; Benkirane, M.; Zhou, Q. Human Polymerase-Associated Factor complex (PAFc) connects the Super Elongation Complex (SEC) to RNA polymerase II on chromatin. Proc. Natl. Acad. Sci. U S A, 2011, 108, E636-645.
161. Chun, T.W.; Finzi, D.; Margolick, J.; Chadwick, K.; Schwartz, D.; Siliciano, R.F. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat. Med. 1995, 1, 1284-1290.
162. Finzi, L.; Gelles, J. Measurement of lactose repressor-mediated loop formation and breakdown in single DNA molecules. Science, 1995, 267, 378-380.
163. Wong, J.K.; Hezareh, M.; Günthard, H.F.; Havlir, D.V.; Ignacio, C.C.; Spina, C.A.; Richman, D.D.; Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science, 1997, 278, 1291-1295.
164. Chun, T.W.; Engel, D.; Mizell, S.B.; Hallahan, C.W.; Fischette, M.; et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat. Med. 1999, 5, 651-655.
165. Stellbrink, H.J.; van Lunzen, J.; Westby, M.; O'Sullivan, E.; Schneider, C.; et al. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS, 2002, 16, 1479-1487.
166. Richman, D.D.; Margolis, D.M.; Delaney, M.; Greene, W.C.; Hazuda, D.; et al. The challenge of finding a cure for HIV infection. Science, 2009, 323, 1304-1307.
167. Scripture-Adams, D.D.; Brooks, D.G.; Korin, Y.D.; Zack, J.A. Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J. Virol. 2002, 76, 13077-13082.
168. Wang, F.X.; Xu, Y.; Sullivan, J.; Souder, E.; Argyris, E.G.; et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J. Clin. Invest. 2005, 115, 128-137.
169. Williams, S.A.; Chen, L.F.; Kwon, H.; Fenard, D.; Bisgrove, D.; Verdin, E.; Greene, W.C. Prostratin antagonizes HIV latency by activating NF-kappaB. J. Biol. Chem. 2004, 279, 42008-42017.
170. Kulkosky, J.; Culnan, D.M.; Roman, J.; Dornadula, G.; Schnell, M.; Boyd, M.R.; Pomerantz, R.J. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood, 2001, 98, 3006-3015.
171. Doyon, G.; Zerbato, J.; Mellors, J.W.; Sluis-Cremer, N. Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog. AIDS, 2013, 27, F7-F11.
172. Xing, S.; Bullen, C.K.; Shroff, N.S.; Shan, L.; Yang, H.C.; et al. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J. Virol. 2011, 85, 6060-6064.
173. Siegel, D.S.; Zhang, X.; Feinman, R.; Teitz, T.; Zelenetz, A.; Richon, V.M.; Rifkind, R.A.; Marks, P.A.; Michaeli, J. Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 162-166.
174. Richon, V.M.; Webb, Y.; Merger, R.; Sheppard, T.; Jursic, B.; Ngo, L.; Civoli, F.; Breslow, R.; Rifkind, R.A.; Marks, P.A. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl. Acad. Sci. U S A, 1996, 93, 5705-5708
175. Choudhary, S.K.; Archin, N.M.; Margolis, D.M. Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells. J. Infect. Dis. 2008, 197, 1162-1170.
176. Contreras, X.M; Barboric, M.; Lenasi, T.; Peterlin, B.M. HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. PLoS Pathog. 2007, 3, 1459-1469.
177. Lehrman, G.; Hogue, I.B.; Palmer, S.; Jennings, C.; Spina, C.A.; et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet, 2005, 366, 549-555.
178. Siliciano, J.D.; Lai, J.; Callender, M.; Pitt, E.; Zhang, H.; et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J. Infect. Dis. 2007, 195, 833-836.
179. Ylisastigui, L.; Archin, N.M.; Lehrman, G.; Bosch, R.J.; Margolis, D.M. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS, 2004, 18, 1101-1108.
180. Siliciano, J.D.; Kajdas, J.; Finzi, D.; Quinn, T.C.; Chadwick, K.; Margolick, J.B.; Kovacs, C.; Gange, S.J.; Siliciano, R.F. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. 2003, Nat. Med. 9, 727-728.
181. Sagot-Lerolle, N.; Lamine, A.; Chaix, M.L.; Boufassa, F.; Aboulker, J.P.; Costagliola, D.; Goujard, C.; Pallier, C.; Delfraissy, J.F.; Lambotte, O. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS, 2008, 22, 1125-1129.
182. Contreras, X.; Schweneker, M.; Chen, C.S.; McCune, J.M.; Deeks, S.G.; Martin, J.; Peterlin, B.M. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J. Biol. Chem. 2009, 284, 6782-6789.
183. Archin, N.M.; Liberty, A.L.; Kashuba, A.D.; Choudhary, S.K.; Kuruc, J.D.; et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012, 487, 482-485.
184. Shan, L.; Deng, K.; Shroff, N.S.; Durand, C.M.; Rabi, S.A.; et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity, 2012, 36, 491-501.
185. Boehm, D.; Calvanese, V.; Dar, R.D.; Xing, S.; Schroeder, S.; et al. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle, 2012, 12 (3) 452-462.
186. Li, Z.; Guo, J.; Wu, Y.; Zhou, Q. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic. Acids. Res. 2012, 41(1) 277-287.
187. Lassen, K.G.; Hebbeler, A.M.; Bhattacharyya, D.; Lobritz, M.A.; Greene, W.C. A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs. PLoS One, 2012, 7, e30176.
188. Sahu, G.K.; Cloyd, M.W. Latent HIV in primary T lymphocytes is unresponsive to histone deacetylase inhibitors. Virol. J. 2011, 8, 400.
189. Hutter, G.; Nowak, D.; Mossner, M.; Ganepola, S.; Mussig, A. et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 2009, 360, 692-698.